A second-generation M1-polarized CAR macrophage with antitumor efficacy.
Lei A, Yu H, Lu S, Lu H, Ding X, Tan T, Zhang H, Zhu M, Tian L, Wang X, Su S, Xue D, Zhang S, Zhao W, Chen Y, Xie W, Zhang L, Zhu Y, Zhao J, Jiang W, Church G, Chan FK, Gao Z, Zhang J.
Lei A, et al.
Nat Immunol. 2024 Jan;25(1):102-116. doi: 10.1038/s41590-023-01687-8. Epub 2023 Nov 27.
Nat Immunol. 2024.
PMID: 38012418
Chimeric antigen receptor (CAR) T cell therapies have successfully treated hematological malignancies. Macrophages have also gained attention as an immunotherapy owing to their immunomodulatory capacity and ability to infiltrate solid tumors and phagocytize tumor cells. .. …
Chimeric antigen receptor (CAR) T cell therapies have successfully treated hematological malignancies. Macrophages have also gained a …